Back to Search
Start Over
Evaluation of Roche Cobas Taqman Quantitative HIV-1 RNA PCR against other HIV-1 commercial viral load tests to examine potential under-quantification
- Source :
- Journal of the International AIDS Society. 11(Suppl 1):P203
- Publisher :
- Springer Nature
-
Abstract
- Background HIV-1 RNA quantification underpins the monitoring of virological response to antiviral therapy, achievement of viral suppression and early identification of viral escape. Most laboratories use commercial HIV-1 RNA viral load tests and the genetic diversity of HIV-1 requires that these are applicable across all subtypes. We introduced the Roche Cobas Ampliprep/Cobas Taqman (CAP/CTM) Real Time Quantitative HIV-1 RNA PCR into diagnostic service after conducting a favourable comparative evaluation of 191 samples with the Roche Cobas Amplicor v1.5 PCR assay [1]. However, concerns were raised when in subsequent routine use we identified 10 patients where there was significant under-quantification (details will be presented, five subtyped all non-B). A separate study reported that Roche CTM was under-quantifying a significant number of samples across a range of subtypes compared to Amplicor [2]. We have undertaken a larger evaluation of CAP/CTM versus Roche Amplicor and have included evaluation of a subset against the Abbott quantitative HIV-1 RNA real-time PCR test.
Details
- Language :
- English
- ISSN :
- 17582652
- Volume :
- 11
- Issue :
- Suppl 1
- Database :
- OpenAIRE
- Journal :
- Journal of the International AIDS Society
- Accession number :
- edsair.doi.dedup.....7307c49db53e8b298e498e060e711a92
- Full Text :
- https://doi.org/10.1186/1758-2652-11-s1-p203